Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.22.1
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]      
Total revenue   $ 10,988 $ 15,633
Seagen      
Disaggregation of Revenue [Line Items]      
Total revenue   312 366
AstraZeneca      
Disaggregation of Revenue [Line Items]      
Total revenue $ 13,000 4,753 14,500
Servier      
Disaggregation of Revenue [Line Items]      
Total revenue   4,734 767
Genentech      
Disaggregation of Revenue [Line Items]      
Total revenue   $ 1,189 $ 0